Department of Pharmacy - Center for Drug Research, Ludwig-Maximilians-Universität München, Munich, Germany.
Coriolis Pharma, Martinsried, Germany.
J Pharm Sci. 2022 Aug;111(8):2288-2298. doi: 10.1016/j.xphs.2022.03.004. Epub 2022 Mar 5.
Adeno-associated virus (AAV) vectors have evolved as one of the most promising delivery systems for gene therapy. The current standard for AAV vector storage is deep-freezing below -60 °C. While this allows for long-term vector storage without loss of activity, it is inconvenient and involves high costs and logistical challenges. Therefore, there is a need for AAV formulations, such as freeze-dried formulations, that allow for long-term storage at 2-8 °C. A major challenge in developing a lyophilization process for complex biological structures like an AAV vector is to minimize the stress on the capsid during the lyophilization cycle. Here, we evaluated different conditions for freeze-drying of AAV8 vectors and found that undesirable instability can be significantly reduced if secondary drying is performed at lower temperatures, kept as short as possible, and the residual moisture is kept between 1.5 and 2%. In a next step, we explored formulations with different salt concentration or excipient compositions and found that a combination of 10 mM phosphate buffer, 5.67% (150 mM) trehalose, 5% hydroxyectoine and 0.1% poloxamer with a residual moisture of approx. 1.5% provided stable long-term storage at 2-8 °C and for at least 4 weeks at 25 °C. These results pave the way for future optimizations of freeze-drying processes for AAV vector-based gene therapy products.
腺相关病毒 (AAV) 载体已发展成为基因治疗最有前途的递送系统之一。AAV 载体储存的当前标准是在-60°C 以下深冻。虽然这允许在不损失活性的情况下进行长期载体储存,但它不方便且涉及高成本和物流挑战。因此,需要 AAV 制剂,例如冻干制剂,允许在 2-8°C 下长期储存。开发用于 AAV 载体等复杂生物结构的冻干工艺的主要挑战是在冻干循环中最大限度地减少对衣壳的压力。在这里,我们评估了不同的 AAV8 载体冻干条件,发现如果在尽可能短的时间内将二次干燥温度保持在较低温度,并将残余水分保持在 1.5%至 2%之间,可以显著降低不理想的不稳定性。在下一步中,我们探索了具有不同盐浓度或赋形剂组成的制剂,并发现 10mM 磷酸盐缓冲液、5.67%(150mM)海藻糖、5%羟基甜菜碱和 0.1%泊洛沙姆的组合,残余水分约为 1.5%,可在 2-8°C 下提供稳定的长期储存,在 25°C 下至少可稳定储存 4 周。这些结果为未来优化基于 AAV 载体的基因治疗产品的冻干工艺铺平了道路。